Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Labcyte and FIMM Announce a Collaboration Enabling “Real-Time” Science to Advance Personalized Medicine in Cancer Treatments

Published: Tuesday, January 08, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Collaboration expected to further the development of personalized medicine in cancer treatment.

Labcyte Inc. and the Institute for Molecular Medicine Finland (FIMM) are collaborating to further the development of personalized medicine in cancer treatment. Labcyte acoustic liquid handling technology has already revolutionized small-molecule research. Now, FIMM, a European leader in advanced research for new cancer therapies, will apply the technology extensively in its personalized medicine programs.

“FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.”
“FIMM’s groundbreaking use of acoustic liquid handling will demonstrate the technology’s role in genetic research,” said Mark Fischer-Colbrie, CEO of Labcyte. “FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.”

FIMM uses large sample sets with links to detailed patient records and genetic data to discover personalized treatment options at a faster pace.

“We see an enormous potential in expanding our use of Labcyte acoustic dispensing technology to help discover specialized leukemia treatments,” said Professor Olli Kallioniemi, director of FIMM. “This research is based on high-throughput drug sensitivity and resistance testing of leukemic cells taken from patients. This new initiative will bring us closer to the clinic and closer to patients.”

“Our aim is to find alternate treatment options for patients who simultaneously undergo treatment in the clinic,” said Kallioniemi. “We will be doing real-time science, using new scientific insights and technologies to help patients who have failed standard leukemia treatments.”

Increasing its throughput enables FIMM to do more rapid and more efficient testing. Researchers at the Institute hope to learn how leukemia cells ex-vivo respond to various types of drugs, and what the resistance mechanisms are. “Larger trials with samples from acute myeloid leukemia patients who have relapsed under standard treatment may quickly suggest individualized treatment options using existing cancer drugs,” added Kallioniemi. “We’re not saying we can cure leukemia, but for patients who have run out of options, alternative treatments may be available sooner.”

By working with FIMM to utilize acoustic liquid handling in genetics research, Labcyte will continue to expand the application of its technology in bio-marker discovery, single-cell analysis, RT-qPCR, genotyping, siRNA screening, and bio-banking.

“We are excited to be an enabling platform for improving patient care with FIMM,” said Fischer-Colbrie. “It will continue to demonstrate how acoustic liquid handling enhances life science research.”

“This research may be changing the way new and emerging drugs are introduced for patients—it is truly game-changing,” said Kallioniemi. “Labcyte technology is a key enabling platform for this drug-sensitivity testing.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Labcyte Inc. Closes $5.3 Million Financing
Privately-held company with products that advance acoustic liquid handling closes a Series D financing.
Thursday, January 10, 2013
Cancer Research Technology Selects the Labcyte Access™ Laboratory Workstation
Labcyte Access workstation to automate the production of assay-ready plates used in CRT's high-throughput cell based screening program
Monday, June 25, 2012
Scientific News
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
Human Evolution Driven by Viruses
Study finds surprising percentage of protein adaptions in humans have been driven by viruses.
Earliest Sign of Alzheimer's Development Discovered
Researchers have identified the first physiological signs of late-onset Alzheimer's disease, underlining the importance of computational power in neurology.
Computational Method Offers Significant Boost in Finding New Cancer Targets
MIT and ARIAD Pharmaceuticals team have identified evidence of significant cancer mutations.
Drug Response Predicted by Cancer Cell Lines
Large-scale study could increase success rate of developing personalised cancer treatments.
Google and EI Partner for Next Generation of Coders
The Earlham Institute's open-source project for visualisation of biological data BioJS acts as mentor organisation for Google Summer of Code 2016.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!